IL304505A - Anti-pdgf-b antibodies and methods of use for the treatment of pulmonary arterial hypertension (PAH) - Google Patents

Anti-pdgf-b antibodies and methods of use for the treatment of pulmonary arterial hypertension (PAH)

Info

Publication number
IL304505A
IL304505A IL304505A IL30450523A IL304505A IL 304505 A IL304505 A IL 304505A IL 304505 A IL304505 A IL 304505A IL 30450523 A IL30450523 A IL 30450523A IL 304505 A IL304505 A IL 304505A
Authority
IL
Israel
Prior art keywords
mehods
pah
pdgf
antibodies
arterial hypertension
Prior art date
Application number
IL304505A
Other languages
English (en)
Hebrew (he)
Inventor
Yinglin Gao
Scott Macdonnell
Bharathi Sundaram
Jee Kim
Priore Isabella Del
Jake Megna
qin Ruan
Original Assignee
Regeneron Pharma
Yinglin Gao
Scott Macdonnell
Bharathi Sundaram
Jee Kim
Priore Isabella Del
Jake Megna
qin Ruan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Yinglin Gao, Scott Macdonnell, Bharathi Sundaram, Jee Kim, Priore Isabella Del, Jake Megna, qin Ruan filed Critical Regeneron Pharma
Publication of IL304505A publication Critical patent/IL304505A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL304505A 2021-01-25 2023-07-17 Anti-pdgf-b antibodies and methods of use for the treatment of pulmonary arterial hypertension (PAH) IL304505A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163141030P 2021-01-25 2021-01-25
PCT/US2022/013666 WO2022159875A1 (en) 2021-01-25 2022-01-25 Anti-pdgf-b antibodies and mehods of use for treating pulmonary arterial hypertension (pah)

Publications (1)

Publication Number Publication Date
IL304505A true IL304505A (en) 2023-09-01

Family

ID=80446637

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304505A IL304505A (en) 2021-01-25 2023-07-17 Anti-pdgf-b antibodies and methods of use for the treatment of pulmonary arterial hypertension (PAH)

Country Status (13)

Country Link
US (2) US12030935B2 (https=)
EP (1) EP4281475A1 (https=)
JP (1) JP2024505195A (https=)
KR (1) KR20230135627A (https=)
CN (1) CN116964088A (https=)
AU (1) AU2022210475A1 (https=)
BR (1) BR112023014337A8 (https=)
CA (1) CA3205846A1 (https=)
CL (1) CL2023002148A1 (https=)
CO (1) CO2023010900A2 (https=)
IL (1) IL304505A (https=)
MX (1) MX2023008691A (https=)
WO (1) WO2022159875A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120028552B (zh) * 2025-02-28 2025-08-19 上海交通大学医学院附属上海儿童医学中心 血小板衍生生长因子pdgf-d在评估右心衰竭中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2136788B1 (en) 2007-03-30 2011-10-26 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
HK1216428A1 (zh) * 2012-11-09 2016-11-11 辉瑞公司 血小板衍生生长因子b之特异性抗体及其组合物和用途
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
CN107148429B (zh) 2014-11-10 2021-12-03 豪夫迈·罗氏有限公司 抗-pdgf-b抗体和使用方法

Also Published As

Publication number Publication date
US20220242943A1 (en) 2022-08-04
KR20230135627A (ko) 2023-09-25
CL2023002148A1 (es) 2024-04-12
AU2022210475A1 (en) 2023-08-10
CO2023010900A2 (es) 2023-08-28
US20240425574A1 (en) 2024-12-26
BR112023014337A8 (pt) 2024-03-05
CA3205846A1 (en) 2022-07-28
MX2023008691A (es) 2023-08-01
EP4281475A1 (en) 2023-11-29
US12030935B2 (en) 2024-07-09
CN116964088A (zh) 2023-10-27
BR112023014337A2 (pt) 2023-09-26
JP2024505195A (ja) 2024-02-05
WO2022159875A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
IL299189A (en) ACTRII proteins for the treatment of pulmonary hypertension (PAH)
HUE067491T2 (hu) Vegyületek és eljárások vírusfertõzések kezelésére
IL304505A (en) Anti-pdgf-b antibodies and methods of use for the treatment of pulmonary arterial hypertension (PAH)
IL316368A (en) Anti-TL1A antibodies and methods of using them
IL264309A (en) Antibodies against Gremlin 1 (grem1) and methods of their use for the treatment of pulmonary hypertension
PL3750619T3 (pl) Sposób wypłukiwania gazów spalinowych z CO2 i/lub SOx
IL319590A (en) Multispecific antibodies and methods of using them
EP4021498A4 (en) Cross-species anti-latent tgf-beta 1 antibodies and methods of use
IL314320A (en) Compounds and methods of use
SMT202500106T1 (it) Anticorpi anti-par-2 e loro metodi d'uso
IL315845A (en) Anti-dectin-1 antibodies and methods of using them
IL291360A (en) Benzimidazoles and methods of using them
IL316065A (en) Anti-CD28 antibodies and methods of using them
IL318694A (en) Antibodies against CCR8 and methods of using them
IL317690A (en) Anti-GPNMB antibodies and methods of using them
IL318512A (en) Methods for treating hypertension using focused, transcranial ultrasound
HK40104155A (en) Anti-pdgf-b antibodies and methods of use for treating pulmonary arterial hypertension (pah)
IL314277A (en) Anti-B7-H3 compounds and methods of use
IL308260A (en) Antibodies against Tigit and methods of using them
IL308815A (en) Selective permeable ring fibers and methods of use
ZA202201160B (en) Anti-grp78 antibodies and method of use thereof
IL280554A (en) Diamond based gem and method of making same
HK40080740A (en) Methods of treating pulmonary arterial hypertension
GB202307639D0 (en) Femoral head removal aid, kits and methods of use
IL321679A (en) Anti-ROR2 antibodies and methods of use